Kimia Biosciences Limited (BOM:530313)

Market Cap	1.58B -10.1%
Revenue (ttm)	1.17B -2.0%
Net Income	74.34M -22.7%
EPS	1.64 -19.2%
Shares Out	47.31M
PE Ratio	20.30
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,762
Open	36.00
Previous Close	36.50
Day's Range	33.06 - 36.00
52-Week Range	23.20 - 86.85
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2026

About Kimia Biosciences

Kimia Biosciences Limited manufactures and sells active pharmaceutical ingredients (APIs) in India. The company offers and develops APIs in the categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, lipid lowering agents, vitamin, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, and anti-bacterial, as well as anti-psychotic, anti-fungal, urologicals, anti-inflammatory, prokinetic agent, cholelithiasis agent, anti-asthmatic, anti-depressant, anti-acne, decongestant, and anti-virals. It exports its prod...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1993
• Employees: 250
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530313

Financial Performance

In fiscal year 2026, Kimia Biosciences's revenue was 1.17 billion, a decrease of -2.03% compared to the previous year's 1.19 billion. Earnings were 74.34 million, a decrease of -22.67%.